deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT06910384

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

An Open Label Study of STR04 in Participants With Amyotrophic Lateral Sclerosis

Sponsor: New England Cell Therapeutics, Inc.

Conditions Amyotrophic Lateral Sclerosis
Interventions STR04
Updated 3 times since 2025 Last updated: Dec 16, 2025 Started: Aug 12, 2025 Primary completion: Dec 16, 2025 Completion: Dec 16, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

organizational restructure

Other Amyotrophic Lateral Sclerosis trials with similar outcome

Browse all Amyotrophic Lateral Sclerosis trials

A PHASE2 clinical study on Amyotrophic Lateral Sclerosis, this trial is terminated or withdrawn. The trial is conducted by New England Cell Therapeutics, Inc. and has accumulated 3 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2025 – ~Oct 2025 · 5 months · monthly snapshotNot Yet Recruiting~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshotRecruiting~Jan 2026 – present · 6 months · monthly snapshotTerminated

Change History

3 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Oct 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. May 2025 — Oct 2025 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • New England Cell Therapeutics, Inc.
Data source: New England Cell Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations